World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 4 March 2013
Main ID:  NCT01377623
Date of registration: 03/01/2011
Primary sponsor: New York University School of Medicine
Public title: Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion
Scientific title: Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion
Date of first enrolment: September 2010
Target sample size: 60
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01377623
Study type:  Observational
Study design:  Observational Model: Cohort, Time Perspective: Prospective  
Countries of recruitment
United States
Contacts
Name:   Michael Urban, MD
Address: 
Telephone:
Email:
Affiliation:  Hospital for Special Surgery, New York
Name:   Alex Bekker, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  NYU School of Medicine
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Adult (> 18) male or female who will undergo surgery for spinal fusion with general
anesthesia.

2. If female, subject is non-lactating and is either:

- Not of childbearing potential

- Of childbearing potential but is not pregnant at time of baseline as determined
by pre-surgical pregnancy testing.

3. Subject is ASA physical status 1, 2, or 3.

Exclusion Criteria:

1. Cognitively impaired (by history)

2. Subject requires chronic antipsychotic history

3. Subject is anticipated to require an additional surgery within 90 days after the
intended spinal fusion

4. Subject known to be in liver failure

5. Subject has received treatment with alpha-2-agonist or antagonist within 2 weeks of
study entry

6. Subject for whom opiates, benzodiazepines, DEX are contraindicated

7. Chronic use of steroids/NSAIDs

8. Patients with serious bradycardia related arrhythmias, i.e. 2nd degree block.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Inflammation
Spinal Stenosis
Intervention(s)
Primary Outcome(s)
Concentration of cytokines (TNF-alpha, IL-1Beta, IL-2, IL-6, IL-10, IFN-gamma) at different time points will be our primary outcome. [Time Frame: Change from baseline cytokin levels]
Secondary Outcome(s)
The secondary outcome parameters would be the quality of recovery score (QoR-40) to measure quality of recovery from surgery and a simple fatigue scale. [Time Frame: Up to 2 weeks before the day of the surgery. On post-operative day 1, 2, 3. And phone follow-ups on day 30 and day 90 after the surgery.]
Secondary ID(s)
10-02185
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Hospira, Inc.
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history